Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

CDC panel: Healthcare workers and nursing home residents should be among first to get COVID-19 vaccine

By Brian Buntz | December 1, 2020

A Centers for Disease Control and Prevention (CDC) advisory panel voted 13 to 1 to prioritize COVID-19 vaccines for healthcare workers and residents of long-term facilities after FDA authorizes their use.  

The panel’s recommendations include three-tiers — Phases 1A, 1B and 1C — for early vaccinations. Officials with the federal government’s Operation Warp Speed have said that state governments will choose who gets COVID-19 vaccines first, but CDC guidance will weigh heavily on the decisionmaking. 

Phase 1A will be the first group. 

Potentially next in line for the vaccines will be essential workers, people with high-risk medical conditions and adults 65 or older, who would fall under Phase 1B in a CDC proposed grouping. 

More than 260 million Americans would fall under the broader proposed Phase 1 vaccination scheme, including 87 non-healthcare workers, more than 100 million adults with high-risk medical conditions and 53 million seniors. “The elderly are much more likely to get severe disease and die,” said epidemiologist Megan Murray in a conversation with Elana Gordon, a journalist at The World. By contrast, the rate of COVID-19 infection among healthcare workers has been lower than expected, Murray said.  

Healthcare workers have a significant risk of contracting the novel coronavirus. As of Nov 21., at least 228,503 healthcare workers had been sickened by the virus. Among them were 822 deaths.

The CDC Advisory Committee on Immunization Practices (ACIP) panel has held a series of meetings since the beginning of the pandemic to discuss topics ranging from vaccine prioritization to adverse event monitoring. 

A vaccine could be available in the coming weeks. Both Pfizer (NYSE:PFE) and Moderna (NSDQ:MRNA) have filed for emergency use authorization for their respective SARS-CoV-2 vaccines. 

The vaccine might not be broadly available until April, May or June of next year, according to the epidemiologist Murray.


Filed Under: Drug Discovery, Infectious Disease
Tagged With: CDC, coronavirus, covid-19, COVID-19 vaccine, FDA, U.S. Centers for Disease Control and Prevention (CDC)
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Secretary of Health removes all current members of the CDC advisory committee on immunization practices
covid-19 vaccine
FDA COVID booster pullback jolts vaccine stocks before gains cool
Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE